Scynexis(SCYX)

1.8635 0.0235 1.2772%

今开:1.98昨收:1.84
最高:1.98 最低:1.8227
涨停价:0.0跌停价:0.0
总市值:7.040265E7

Scynexis的热门讨论

超过5%股东持股披露「修订」

Scynexis(SCYX)02-14 05:35

$Scynexis(SCYX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000935836-24-000141  Act: 34  Size: 59 KB 网页链接查看全文

股东委托书协议

Scynexis(SCYX)04-26 04:45

$Scynexis(SCYX)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-022086  Act: 34  Size: 2 MB 网页链接查看全文

其他

Scynexis(SCYX)04-26 04:45

$Scynexis(SCYX)$ ARS Annual Report to Security Holders Accession Number: 0001140361-24-022094  Act: 34  Size: 682 KB 网页链接查看全文

季度财报

Scynexis(SCYX)05-09 04:05

$Scynexis(SCYX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055590  Act: 34  Size: 8 MB 网页链接查看全文

持股变动声明

Scynexis(SCYX)02-17 06:55

$Scynexis(SCYX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-016578  Size: 4 KB 网页链接查看全文

超过5%股东持股披露「修订」

Scynexis(SCYX)02-14 09:45

$Scynexis(SCYX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001218  Act: 34  Size: 201 KB 网页链接查看全文

年度财报

Scynexis(SCYX)03-29 04:25

$Scynexis(SCYX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-038046  Act: 34  Size: 12 MB 网页链接查看全文

证券出售报告

Scynexis(SCYX)02-10 06:15

$Scynexis(SCYX)$ 144 Report of proposed sale of securities Accession Number: 0001623632-24-000234  Act: 33  Size: 6 KB 网页链接查看全文

超过5%股东持股披露「修订」

Scynexis(SCYX)02-14 10:15

$Scynexis(SCYX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001223  Act: 34  Size: 125 KB 网页链接查看全文

当期报告

Scynexis(SCYX)03-29 04:15

$Scynexis(SCYX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-038015  Act: 34  Size: 400 KB 网页链接查看全文

1 2

Scynexis的新闻

翰森制药(03692)将获得治疗阴道酵母菌感染药ibrexafungerp在中国研发及商业化的独家特许权

智通财经APP讯,翰森制药(03692)公布,于2021年2月11日,翰森(上海)健康科技有限公司及江苏豪森药业集团有限公司(统称为“被许可人”,各自为该公司的全资附属公司)已与SCYNEXIS, Inc.(纳斯达克股份代号:SCYX)订立独家许可及合作协议。... 网页链接

Scynexis的公告

季度财报

$Scynexis(SCYX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055590  Act: 34  Size: 8 MB 网页链接

股东委托书协议

$Scynexis(SCYX)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-022086  Act: 34  Size: 2 MB 网页链接

其他

$Scynexis(SCYX)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001140361-24-022093  Act: 34  Size: 7 MB 网页链接

其他

$Scynexis(SCYX)$ ARS Annual Report to Security Holders Accession Number: 0001140361-24-022094  Act: 34  Size: 682 KB 网页链接

员工持股计划

$Scynexis(SCYX)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0000950170-24-038086  Act: 33  Size: 193 KB 网页链接

年度财报

$Scynexis(SCYX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-038046  Act: 34  Size: 12 MB 网页链接

当期报告

$Scynexis(SCYX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-038015  Act: 34  Size: 400 KB 网页链接

持股变动声明

$Scynexis(SCYX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-016578  Size: 4 KB 网页链接

超过5%股东持股披露「修订」

$Scynexis(SCYX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001223  Act: 34  Size: 125 KB 网页链接

超过5%股东持股披露「修订」

$Scynexis(SCYX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000919574-24-001218  Act: 34  Size: 201 KB 网页链接

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40